Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 8/20 | 0.70 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.40 |
| ▸ | AKR1C2 | P52895 | 2/20 | 0.40 |
| ▸ | APP | P05067 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4813224 | 0.98 | HDAC4 (0.68) | HDAC4AKR1C1MAPTKMT2AAKR1C3 | |
| SCHEMBL20242254 | 0.93 | HDAC4 (0.60) | HDAC4AKR1C1MAPTKMT2AAKR1C3 | |
| SCHEMBL4807187 | 0.85 | HDAC4 (0.68) | HDAC4MAPTKMT2APSEN1PSEN2 | |
| SCHEMBL25303177 | 0.84 | AKR1C1 (0.52) | HDAC4AKR1C1AKR1C3AKR1C2APP | |
| SCHEMBL16132812 | 0.83 | HDAC4 (1.00) | HDAC4 | |
| SCHEMBL31294736 | 0.80 | AKR1C1 (0.45) | HDAC4AKR1C1KMT2AAKR1C3AKR1C2 | |
| SCHEMBL9314481 | 0.80 | AKR1C1 (0.45) | HDAC4AKR1C1AKR1C3AKR1C2APP | |
| SCHEMBL20242061 | 0.79 | HDAC4 (0.60) | HDAC4MAPTKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL10528639 | 0.78 | HDAC4 (0.59) | HDAC4MAPTKMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL28295066 | 0.77 | HDAC4 (0.47) | HDAC4AKR1C1KMT2AAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | claimed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | claimed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | claimed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | claimed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | claimed |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| EP-1910316-B1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | HOFFMANN LA ROCHE (CH) | 2010-11-10 | — | — | EP | disclosed |
| EP-1910316-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. Hoffmann-Roche AG (CH) | 2008-04-16 | — | — | EP | disclosed |
| US-7268154-B2 | Substituted triazole compounds | HOFFMAN-LA ROCHE INC. (US) | 2007-09-11 | — | — | US | disclosed |
| WO-2007012579-A1 | SUBSTITUTED TRIAZOLE DERIVATIVES AND THEIR USE AS NEUROKININ 3 RECEPTOR ANTAGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-02-01 | — | — | WO | disclosed |
| US-20070021475-A1 | Substituted triazole derivatives | HOFFMANN-LA ROCHE INC. | 2007-01-25 | — | — | US | disclosed |
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | MILLENNIUM PHARMACEUTICALS, INC. | 2005-06-30 | — | — | US | disclosed |
| WO-2003037271-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREFOR | MILLENNIUM PHARMACEUTICALS,INC. (US) | 2003-05-08 | — | — | WO | disclosed |
| EP-1091958-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2001-04-18 | — | — | EP | disclosed |
| WO-2000001692-A1 | SALTS OF PAROXETINE | SMITHKLINE BEECHAM PLC (GB) | 2000-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143372-A1 | Compounds, pharmaceutical compositions and methods of use therefor | CCR8, CCL11, CCR5 | HDAC4 3484/4885AKR1C1 427/4885MAPT 3042/4885 |
| US-20070021475-A1 | Substituted triazole derivatives | GPR3, GRIN3A, GRIK3 | HDAC4 758/4885AKR1C1 656/4885MAPT 2343/4885 |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | HDAC4 1227/4885AKR1C1 277/4885MAPT 1125/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.